0.38
0.38 (0%)
As of Jun 06, 2024
Neubase Therapeutics, Inc. [NBSE]
Source:
Company Overview
Neubase Therapeutics, Inc. have designed, built, and validated a new technology platform that can uniquely Drug the Genome to address the three disease-causing mechanisms, without the limitations of early precision genetic medicines.
| Country | United States |
| Headquarters | pittsburgh, pennsylvania |
| Phone Number | 412-763-3350 |
| Industry | manufacturing |
| CEO | Dietrich A. Stephan |
| Website | neubasetherapeutics.com |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | |
| Operating Profit | $-2.8 |
| Net Income | $-1.8 |
| Net Cash | $-4.8 |
Profit Ratios
| Gross Margin | |
| Operating Margin | |
| Profit as % of Revenues | |
| Profit as % of Assets | -8.2% |
| Profit as % of Stockholder Equity | -19.9% |
Management Effectiveness
| Return on Equity | -19.9% |
| Return on Assets | -9.8% |
| Turnover Ratio | |
| EBITA |
Balance Sheet and Cash Flow Measures
| Total Assets | $18.6 |
| Total Liabilities | $9.5 |
| Operating Cash Flow | $-9.1 |
| Investing Cash Flow | $-0 |
| Financing Cash Flow | $4.3 |
